Copaxone disappoints at higher dose

Shares of Israel's Teva Pharmaceuticals slid after the company announced that a late-stage trial of a higher dose of its MS drug Copaxone did not perform better than a standard dose. Report

Suggested Articles

Two weeks after receiving a second dose of Moderna's COVID-19 jab, patients had "robust" levels of neutralizing antibodies against the…

Despite questions about eye-related side effects, GlaxoSmithKline's anti-BCMA treatment emerged from an advisory committee meeting with a 12-0 vote.

After Mallinckrodt's terlipressin beat placebo at reversing kidney failure, an FDA panel will discuss the phase 3 trial's surrogate endpoint.